SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Stroke

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: LJM4/22/2006 10:08:58 PM
   of 70
 
Antiplatelets Recommended For Prevention Of Recurrent Stroke Or Death


Main Category: Stroke News
Article Date: 22 Apr 2006 - 0:00am (PDT)

Results of the Warfarin-Aspirin Recurrent Stroke Study published in the journal "Cerebrovascular Diseases" show no benefit of warfarin over aspirin for the prevention of recurrent stroke or death. Therefore, pending future clinical trial evidence to the contrary, antiplatelets are recommended for survivors of noncardioembolic stroke.

The efficacy of adjusted-dose warfarin to aspirin for recurrent ischemic stroke or death within 2 years was compared among prespecified and exploratory subgroups with respect to sociodemographic and vascular risk factors, stroke subtype, arterial territory, and infarct topography. Hazard ratios and 95% confidence intervals comparing warfarin to aspirin were calculated using Cox proportional hazards models. Differences in hazard ratios were tested using interaction terms.

No treatment differences between warfarin and aspirin were found across multiple prespecified subgroups. In a multivariate model, warfarin was associated with a greater hazard among patients with moderate stroke severity and a greater benefit among those with posterior circulation location without brainstem infarction. In post-hoc analyses of the cryptogenic subgroup, warfarin was associated with worse outcomes among patients with moderate stroke severity and better outcomes among those without baseline hypertension or with posterior circulation infarcts sparing the brainstem

About the S. KARGER AG

With over a century of experience in connecting the world of biomedical science, Karger publishes nearly 80 scientific, peer-reviewed journals and 150 serial and non-serial books and supplement issues annually for a global scientific readership.

karger.com

Sacco RL, Prabhakaran S, Thompson JLP, Murphy A, Sciacca RR, Levin B, Mohr J-P, on behalf of the WARSS Investigators:
Comparison of Warfarin versus Aspirin for the Prevention of Recurrent Stroke or Death: Subgroup Analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc Dis
2006;22:4-12 (DOI:10.1159/000092331
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext